Document hub

Our international presence

Return to Hikma.com
Contact Us

Popular searches

Our impact

We are shaping a healthier world by expanding our patient reach across our markets. As we grow as a business, we are able to enhance the positive impact we have.

Making a positive impact for all stakeholders

Our purpose is to put better health within reach, every day for
healthcare professionals and patients.

We engage healthcare professionals to better understand their needs, helping them treat the patients they serve. 

Our employees have always been at the heart of everything we do.

We promote employee development and growth, ensure their health and safety, and cultivate a diverse and inclusive environment

The passion and commitment of our people to our values is key to delivering our purpose and supports our growth plans. One of our key strategic priorities is to build a culture that inspires and enables our people, one in which they are empowered to drive innovation and are committed to caring for customers, patients and communities around the world.

Our customers are our business partners and we are
committed to providing them with a consistent and reliable
supply of high-quality medicines.

We work closely with Group Purchasing Organisations (GPOs), hospitals, retailers, wholesalers and others to build strong relationships and enhance service levels.

We are a responsible and sustainable company and have a duty of care towards our communities and the environment.

Since its inception, Hikma has been dedicated to transforming people’s lives by providing the medicines they need and supporting the communities where we live and work. Making positive contributions to the communities where we operate, and providing assistance to those in need, supports long-term, sustainable growth, while positively impacting society.

We also strive to minimise our environmental impacts and are committed to making our operations more energy efficient.

Highlights
262 million patients treated
132 product launches in 2024
$4.1 million worth of medicines (value based on cost of goods)
17% reduction in Scope 1 and 2 emissions since base year 2020

Hikma's role in delivering essential medicines to those in need is of great importance. It is a responsibility that we must all take seriously. I remain wholeheartedly committed to ensuring that we act responsibly and deliver a profoundly positive impact on patients, communities, and the environment.

Riad Mishlawi, CEO

Useful documents

Hikma Annual Report 2024 Hikma Sustainability Report 2024
Related content

Explore more

Number of patients reference: Based on internal analysis by Hikma Pharmaceuticals PLC using data from the following source: IQVIA Analytics Link Q4 2024 for the calendar year 2021, 2022, 2023 and 2024, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved. Methodology: Drug-treated patient values are derived by converting disease-specific volume sales for each drug to estimated treated patient numbers, adjusted for dosing, duration and compliance, but not concomitance.